March 9, 2006Journal of Hypertension
Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move
Key result
High plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with cardiovascular mortality in end-stage renal disease and predict renal disease progression and death.
Why the study?
Is high plasma asymmetric dimethylarginine (ADMA) associated with increased cardiovascular and renal risk?
Population
Patients with end-stage renal disease, moderate to severe renal insufficiency, and males in the general…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports ADMA as prognostic biomarker in ESRD; hypothesis-generating for targeted interventions.
Structured PICO
Is high plasma asymmetric dimethylarginine (ADMA) associated with increased cardiovascular and renal risk?
P
Population
Patients with end-stage renal disease, moderate to severe renal insufficiency, and males in the general population
E
Exposure
High plasma concentration of asymmetric dimethylarginine (ADMA)
O
Outcome
Cardiovascular and renal outcomes (intima-media thickening, left ventricular hypertrophy, all-cause and cardiovascular mortality, coronary events, renal disease progression)
ADMA is a significant biomarker linking atherosclerosis and renal insufficiency, predicting adverse cardiovascular and renal outcomes.
Cite This Study
Carmine Zoccali (2006) conducted a review in Renal insufficiency and cardiovascular risk. Asymmetric dimethylarginine (ADMA) was evaluated. High plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with cardiovascular mortality in end-stage renal disease and predict renal disease progression and death.